How to Get Tresiba in South Carolina

What Is Tresiba and Why Patients in South Carolina Request It

Tresiba is the brand name for insulin degludec, a long-acting basal insulin approved by the FDA in September 2015 for adults and children aged 1 year and older with type 1 or type 2 diabetes [1]. Its distinctive pharmacokinetic profile sets it apart from older basal insulins: the half-life exceeds 25 hours and the duration of action stretches beyond 42 hours, producing a flatter, more stable glucose-lowering effect compared with insulin glargine U-100 [2].

The DEVOTE trial (N=7,637, published in the New England Journal of Medicine, 2017) compared insulin degludec with insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk [3]. Degludec met the non-inferiority threshold for major adverse cardiovascular events (MACE) and produced a 27% lower rate of severe hypoglycemia (rate ratio 0.73 to 95% CI 0.60 to 0.89, P<0.001) [3]. That hypoglycemia advantage drives many South Carolina clinicians to consider Tresiba for patients with hypoglycemia unawareness, variable schedules, or prior episodes of nocturnal low blood sugar.

South Carolina had an estimated 571,000 adults living with diagnosed diabetes as of the most recent CDC state surveillance data, roughly 14.7% of the adult population [4]. Access to newer basal insulins like degludec remains uneven across the state, particularly in rural counties, which makes telehealth prescribing pathways especially relevant for patients outside Columbia, Greenville, or Charleston.

Who Can Prescribe Tresiba in South Carolina

Any licensed prescriber with authority over Schedule V or prescription-only medications in South Carolina can write for Tresiba. That group includes physicians (MD/DO), nurse practitioners operating under full practice authority, and physician assistants working within a supervising physician agreement.

South Carolina granted nurse practitioners full practice authority effective January 1, 2022, under S.C. Code Ann. Section 40-33-34 [5]. A certified nurse practitioner with a diabetes or endocrinology specialty background can now diagnose, order labs, and prescribe insulin degludec without physician co-signature. Physician assistants still require a supervising physician agreement on file with the South Carolina Board of Medical Examiners, though the supervising physician does not need to be physically present at the time of prescribing [6].

Endocrinologists remain the most common specialists to initiate Tresiba, particularly for type 1 patients or those with complex titration needs. Primary care physicians, internal medicine providers, and family medicine practitioners routinely prescribe degludec for type 2 patients as well. The American Diabetes Association 2024 Standards of Care note that basal insulin analogs with longer duration, including degludec, are preferred over NPH insulin to reduce hypoglycemia risk [7].

How to Get a Tresiba Prescription Through Telehealth in South Carolina

South Carolina permits telehealth prescribing for non-controlled prescription medications, and insulin degludec is not a controlled substance. State law (S.C. Code Ann. Section 44-7-2910 et seq.) requires that a valid patient-provider relationship be established before prescribing, but that relationship may be established via synchronous audio-video visit [8].

The standard telehealth workflow for Tresiba in South Carolina runs as follows. First, schedule a video visit with a licensed South Carolina telehealth provider. Second, share recent labs (fasting glucose, HbA1c, basic metabolic panel, and any CGM data). Third, the provider reviews your history, confirms the diagnosis of diabetes, and calculates an appropriate starting dose. Fourth, the prescription is sent electronically to a pharmacy of your choice, including mail-order pharmacies that ship to South Carolina addresses.

Most telehealth platforms serving South Carolina complete the prescribing step on the same day as the visit. Pharmacy processing and shipping add 2 to 5 business days for standard mail-order fulfillment or same-day to next-day turnaround at a local retail pharmacy.

HealthRX physicians follow an initial degludec dosing protocol based on the FDA-approved labeling: insulin-naive type 2 patients typically start at 10 units subcutaneously once daily, while patients converting from another basal insulin start at a unit-to-unit dose [1]. Dose titration by 2 units every 3 days targets a fasting glucose of 80 to 130 mg/dL, consistent with ADA 2024 glycemic targets [7].

What Labs Are Needed Before Tresiba Is Prescribed in South Carolina

Labs are not legally required before prescribing insulin degludec, but responsible clinical practice in South Carolina follows ADA and AACE guidelines that call for baseline metabolic data [7]. Expect your provider to review or order the following before or at the time of your first Tresiba prescription.

Hemoglobin A1c confirms the diagnosis and establishes a treatment baseline. An HbA1c at or above 6.5% meets the ADA diagnostic threshold for diabetes [7]. A basic metabolic panel (BMP) checks renal function because insulin clearance slows in chronic kidney disease, potentially increasing hypoglycemia risk [9]. A fasting plasma glucose or continuous glucose monitor (CGM) download gives the provider a real-time picture of glycemic variability. Thyroid function (TSH) is checked when autoimmune type 1 diabetes is suspected, as Hashimoto thyroiditis co-occurs in roughly 17 to 30% of type 1 patients [10].

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm specifies that all patients initiating basal insulin should have an HbA1c, fasting glucose, and renal function assessed at initiation and every 3 months until targets are reached [11]. South Carolina telehealth providers typically send lab orders to a local Quest or LabCorp draw site if the patient lacks recent results.

Pharmacy Access for Tresiba in South Carolina

Tresiba is commercially available at most major retail pharmacy chains operating in South Carolina, including CVS, Walgreens, Walmart, and Publix. It is stocked as a 3 mL FlexTouch pen (100 units/mL and 200 units/mL concentrations) and as 10 mL vials (100 units/mL) [1].

Retail cash prices without insurance run approximately $350 to $430 per 5-pack of FlexTouch pens (U-100). The Novo Nordisk patient assistance program, Novo Nordisk Patient Assistance Program (PAP), provides Tresiba at no cost to qualifying uninsured patients with household income at or below 400% of the federal poverty level [12]. Patients with commercial insurance who meet income criteria may also use the Novo Nordisk savings card to pay as little as $99 per month.

South Carolina-licensed 503A compounding pharmacies may compound insulin formulations for individual patient prescriptions, but they cannot legally compound a copy of an FDA-approved commercially available drug like Tresiba without a documented clinical rationale for the deviation [13]. If a physician documents a specific medical need, such as a concentration not commercially available, a 503A pharmacy can prepare a custom formulation. Standard insulin degludec 100 units/mL does not meet that threshold because it is commercially available; patients requiring non-standard concentrations should work with their provider to document the clinical justification.

Prior Authorization for Tresiba in South Carolina

Most commercial insurers and managed care organizations operating in South Carolina require prior authorization (PA) before covering Tresiba. South Carolina Medicaid (Healthy Connections) does not currently include insulin degludec on its preferred drug list and does not cover it [14]. Patients covered by Medicaid should discuss alternatives such as insulin glargine U-300 (Toujeo) or insulin detemir (Levemir), both of which appear on the Healthy Connections PDL, with their provider.

For commercial plans, the PA process typically requires documentation of a diabetes diagnosis (ICD-10 code E10.x or E11.x), evidence of suboptimal glycemic control on a prior basal insulin (HbA1c above target after at least 90 days of optimized dosing), and documentation of at least one episode of clinically significant hypoglycemia or a clinical reason the patient cannot tolerate the first-line formulary basal insulin [15].

The DEVOTE trial data are directly relevant to PA appeals. Citing the 27% reduction in severe hypoglycemia rate (rate ratio 0.73, P<0.001) [3] and the patient's own documented hypoglycemia history gives the prescribing provider evidence-based grounds for a medical necessity appeal. South Carolina law requires commercial insurers to provide a PA determination within 72 hours for urgent requests and 15 calendar days for standard requests under the South Carolina Insurance Code [16].

"Insulin degludec offers a clinically meaningful reduction in severe hypoglycemia compared with glargine U-100, and that evidence should anchor any medical necessity argument for patients who have experienced nocturnal hypoglycemia on their current regimen," according to prescribing guidance reviewed by the HealthRX medical team.

Transferring an Existing Tresiba Prescription to South Carolina

Patients relocating to South Carolina with an active Tresiba prescription from another state can transfer the prescription to any South Carolina-licensed retail pharmacy. Under the South Carolina Pharmacy Practice Act and Board of Pharmacy regulations, a pharmacist may accept a transfer of a valid prescription for a non-controlled substance from an out-of-state pharmacy [17].

Call the South Carolina pharmacy you wish to use and provide the name, phone number, and address of your current pharmacy. The receiving pharmacist contacts the dispensing pharmacy directly. For mail-order prescriptions, update the ship-to address with your mail-order pharmacy and verify they are licensed to ship to South Carolina. Most national mail-order pharmacies, including Express Scripts, OptumRx, and CVS Caremark, hold South Carolina non-resident pharmacy licenses and can ship to SC addresses without interruption.

If your prescription has no remaining refills, your new South Carolina provider can write a new prescription at or after your first visit. Most providers will review the prior prescription details and carry over the same dose if glycemic control has been stable. The ADA recommends HbA1c reassessment every 3 months when changing insulin regimens [7], so plan a lab draw within 90 days of the transfer.

Dosing Basics and Titration in South Carolina Clinical Practice

The FDA-approved starting dose for insulin-naive adults with type 2 diabetes is 10 units subcutaneously once daily [1]. For type 1 adults, degludec is typically initiated as part of a basal-bolus regimen at approximately one-third of the total daily insulin dose, consistent with established split-dose principles [1].

Degludec's ultra-long action means the injection time can shift by up to 8 hours without significant glycemic impact, according to data from a dedicated timing flexibility study published in Diabetes Care [18]. This is particularly useful for South Carolina patients with overnight shift work, variable meal schedules, or travel across time zones. Conventional basal insulins like glargine U-100 require more rigid timing to maintain stable trough levels.

Injection sites include the abdomen, thigh, or upper arm. Rotating sites within the same body region each day reduces lipohypertrophy. The SWITCH 1 and SWITCH 2 crossover trials (published in Diabetes Care) confirmed that switching from glargine U-100 to degludec reduced overall symptomatic hypoglycemia by 11% in type 1 (P<0.001) and by 30% in type 2 diabetes (P<0.001) in a real-world crossover design [19].

Storage: unopened Tresiba pens and vials are refrigerated at 36 to 46°F. Once in use, pens may be kept at room temperature (below 86°F) for up to 56 days, a longer in-use period than glargine U-100 (28 days) that benefits patients during South Carolina's hot summers [1].

What to Expect at Your First South Carolina Tresiba Appointment

Plan for a 20 to 40 minute visit, whether in-person or via video. The provider will confirm your diabetes diagnosis type, review prior insulin history, calculate your starting degludec dose, and address injection technique if you are insulin-naive. They will also discuss hypoglycemia recognition and treatment, because even the lower hypoglycemia rate seen in DEVOTE does not mean hypoglycemia is impossible.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) defines severe hypoglycemia as a blood glucose below 54 mg/dL or any episode requiring assistance from another person [20]. South Carolina patients should keep fast-acting glucose (15 to 20 grams of simple carbohydrate) on hand and instruct a household member in glucagon administration if they are at elevated risk.

Bring to your visit: your most recent HbA1c result (ideally within 90 days), a list of current medications including any other diabetes drugs, your insurance card, and if you use a CGM, a downloaded report showing at least 14 days of data. A CGM report gives the prescriber time-in-range data that a single fasting glucose cannot provide, and the ADA 2024 Standards of Care now recommend at least 70% time in range (70 to 180 mg/dL) as a supplemental glycemic target alongside HbA1c [7].

Comparing Tresiba to Other Basal Insulins Available in South Carolina

South Carolina pharmacies stock all major basal insulins: insulin glargine U-100 (Lantus, Basaglar), insulin glargine U-300 (Toujeo), insulin detemir (Levemir), and insulin degludec (Tresiba). Each has a distinct pharmacokinetic profile and formulary status.

Glargine U-100 has the longest formulary track record and the broadest SC Medicaid coverage, but its 24-hour duration leaves some patients with a trough hypoglycemia window in the early morning hours. Glargine U-300 has a flatter profile than U-100 and lower nocturnal hypoglycemia rates, documented in the EDITION trials [21], though its duration is still shorter than degludec. Detemir has a dose-dependent duration of 16 to 24 hours and typically requires twice-daily dosing in type 1 patients, adding injection burden.

Degludec's 42-plus-hour action profile produces the most pharmacodynamically stable basal coverage currently available in the South Carolina market. A 2019 meta-analysis in Diabetes, Obesity and Metabolism (N=32 randomized controlled trials) confirmed that degludec reduced nocturnal hypoglycemia risk versus glargine U-100 with a relative risk of 0.63 (95% CI 0.55 to 0.73) [22]. For patients who have experienced repeated nocturnal lows on glargine, the clinical case for switching to degludec is supported by this level of evidence.

Cost remains the primary barrier. Until South Carolina Medicaid adds degludec to its PDL, uninsured and Medicaid patients will need to rely on Novo Nordisk's assistance programs or discuss a formulary-covered alternative with their provider.